Antibody–drug conjugates (ADC) are an inevitable trend in the development of modern “precision medicine”. The goal of this work is to produce enzyme-responsive antibody nanoparticle-loaded medication (FMSN-Dox-H2-AE01) based on the EGFR antibody (AE01) and human serum albumin (HSA) shelled mesoporous silica nanoparticles. HSA and antibodies on the surface of the particlescan not only enhance the biocompatibility of the particle and avoid early drug leakage but also allow selective biodegradation triggered by matrix metalloproteinase-2 (MMP-2), which are overexpressed enzymes in some tumor tissues. The cytotoxicity test confirmed favorable safety and efficacy of the ADC. The mortality rate of cancer cells is about 85–90%. Moreover, the antibody nanoparticle-loaded drug showed distinguishing controlled release efficiency toward cancer cells induced by different levels of MMP-2 and pH. This enzyme-responsive FMSN-Dox-H2-AE01 offers a promising option for cancer therapy.

中文翻译：

---

构建肿瘤靶向和 MMP-2 生物可裂解抗体偶联二氧化硅纳米颗粒用于有效的癌症治疗

抗体偶联药物（ADC）是现代“精准医学”发展的必然趋势。这项工作的目标是生产基于 EGFR 抗体 (AE01) 和人血清白蛋白 (HSA) 壳介孔二氧化硅纳米颗粒的酶反应性抗体纳米颗粒负载药物 (FMSN-Dox-H2-AE01)。颗粒表面的 HSA 和抗体不仅可以增强颗粒的生物相容性，避免早期药物泄漏，而且还允许由基质金属蛋白酶 2 (MMP-2) 触发的选择性生物降解，基质金属蛋白酶 2 是一些肿瘤组织中过表达的酶。细胞毒性试验证实了 ADC 的良好安全性和有效性。癌细胞的死亡率约为 85-90%。而且，抗体纳米颗粒负载的药物对不同水平的 MMP-2 和 pH 诱导的癌细胞显示出不同的控释效率。这种酶反应性 FMSN-Dox-H2-AE01 为癌症治疗提供了一个有前途的选择。